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Abstract
Background: The Brazilian response towards AIDS epidemic is well known, but the absence of a systematic review of 
vulnerable populations ? men who have sex with men (MSM), female sex workers (FSW), and drug users (DU) remains a 
main gap in the available literature. Our goal was to conduct a systematic review and meta-analysis of studies assessing 
HIV prevalence among MSM, FSW and DU, calculating a combined pooled prevalence and summarizing factors 
associated the pooled prevalence for each group.
Methods: Nine electronic databases (MEDLINE via PubMed, EMBASE, Cochrane CENTRAL, AIDSLINE, AMED, CINAHL, 
TOXNET, SciELO, and ISI-Web of Science) were searched for peer-reviewed papers published in English, French, Spanish 
or Portuguese, from 1999 to 2009. To be included in the review, studies had to measure HIV prevalence and/or 
incidence as the primary outcome among at least one specific population under analysis.
Results: The studies targeting the three populations analyzed mostly young participants aged 30 years or less. Among 
FSW, eight studies were selected (3,625 participants), consistently identifying higher condom use with sexual clients 
than with occasional and stable partners. The combined HIV prevalence for FSW was 6.2 (95% CI: 4.4-8.3). Ten studies 
targeting MSM were identified (6,475 participants). Unprotected anal intercourse was commonly reported on those 
studies, but with great variability according to the nature of the relationship - stable vs. occasional sex partners - and 
sexual practice - receptive vs. insertive anal sex. Pooled HIV prevalence for MSM was 13.6 (95% CI: 8.2-20.2). Twenty nine 
studies targeting DU were identified (13,063 participants). Those studies consistently identified injection drug use and 
syringe/needle sharing as key predictors of HIV-infection, as well as engagement in sex work and male-to-male sex. The 
combined HIV prevalence across studies targeting DU was 23.1 (95% CI: 16.7-30.2).
Conclusions: FSW, MSM and DU from Brazil have a much risk of acquiring HIV infection compared to the general 
population, among which HIV prevalence has been relatively low (~0.6%). Those vulnerable populations should be 
targeted by focused prevention strategies that provide accurate information, counseling and testing, as well as 
concrete means to foster behavior change (e.g. access to condoms, drug abuse treatment, and clean syringes in the 
case of active injecting drug users), tailored to gender and culture-specific needs. Programs that provide these services 
need to be implemented on public health services throughout the country, in order to decrease the vulnerability of 
those populations to HIV infection.
Background
HIV/AIDS is the largest pandemic ever faced by human-
kind, with over 30 million people living with HIV/AIDS
(PLWHA) worldwide. Over 95% of new infections since
2003 have been reported in low and middle-income
countries. According to the UNAIDS, "for every two peo-
ple who start taking antiretroviral drugs, another five
become newly infected. Unless we take urgent steps to
intensify HIV prevention we will fail to sustain the gains
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of the past few years, and universal access will simply be a
noble aspiration."[1].
Among the 135 low- and middle-income countries
mentioned in a recently released report, UNAIDS esti-
mates that 97 (71.8%) countries have low-level or concen-
trated HIV/AIDS epidemics [2]. In a concentrated
epidemic, HIV spreads rapidly in one or more specific
subpopulations, but its spread has been relatively modest
in the general population. In these contexts the networks
of at-risk populations have a key role in the epidemic
dynamics. The future course of the epidemic is deter-
mined by the nature and intensity of the interactions
between subpopulations with high infection rates and the
general population [3-5]. To reduce the likelihood that a
low-level or concentrated epidemic may become a gener-
alized epidemic, prevention programs should focus on
potential epidemiological bridges, such as the sex part-
ners of injecting drug users (IDU), female sex workers
(FSW) or truck drivers [6,7].
Most countries from Latin America have been affected
by concentrated HIV/AIDS epidemics and HIV infection
rates in this region have changed little in the past decade.
HIV transmission is occurring primarily among men who
have sex with men - MSM [8,9], and (to a lesser extent)
among FSW, IDU and non-injection drug users - NIDU
[10].
In Brazil, AIDS prevalence among the general popula-
tion has been low in recent years: 0.6% -- 0.4% among
women and 0.8% among men [11]. The Brazilian commit-
ment towards building and sustaining a timely and com-
prehensive HIV/AIDS prevention and treatment
program can potentially pave the way for other develop-
ing countries with similar concentrated epidemics [12].
Brazil was the first middle-income country to provide
free and universal access to highly active antiretroviral
therapy (HAART), laboratory monitoring and clinical
care at no cost at the point of health care delivery to any
eligible patient, since 1996 [13,14]. As of the end of 2009,
approximately 200,000 patients were receiving HAART
in Brazil, all of them monitored by regular CD4+ count
and viral load tests (and genotyping, if it is necessary),
making it the most comprehensive HIV treatment initia-
tive implemented by a middle-income country, world-
wide [15-17]. Brazil has also implemented prevention
initiatives targeting both the general population and dif-
ferent at-risk populations [18].
Despite being one of the first countries to implement
free and universal access to HAART, together with a con-
certed array of prevention strategies, only recently Brazil
has implemented comprehensive biological and behav-
ioral surveillance surveys (BSS) to monitor trends of HIV
infection rates (together with other sexually transmitted
infections and blood-borne infections) among the most
at-risk groups: MSM, FSW, IDU and NIDU.
In the absence of reliable biological and BSS data on
most at-risk populations, HIV/AIDS prevalence rates
represent the best information about the current status of
the HIV epidemic in the country [1]. This information is
vital to inform health planning, resources allocation and
might also be an important tool for advocacy and the
elaboration of future scenarios [1]. Trying to contribute
for a better understanding of the HIV/AIDS epidemic in
Brazil, a country with a concentrated epidemic, we con-
ducted a systematic review followed by meta-analysis.
Our study summarizes the peer-reviewed literature on
HIV prevalence among populations under increased risk
of acquiring HIV infection in Brazil and presents a pooled
HIV prevalence for the following populations: FSW,
MSM and IDU/NIDU.
Methods
In planning a systematic review and meta-analysis, we
reviewed standard guidelines to conduct and report
meta-analysis studies, which included the Consolidated
Standards of Reporting Trials - CONSORT [19,20], the
Quality of Reporting of Meta-analyses - QUOROM [21],
the Meta-analysis of Observational Studies in Epidemiol-
ogy (MOOSE) Group [22], and the Transparent Report-
ing of Evaluations with Nonrandomized Designs -
TREND [23]. As only observational studies rather than
clinical trials have been found, the MOOSE recommen-
dations were used to conduct and report the findings
from the meta-analysis, while the TREND checklist (Ver-
sion 1.0) was used as a guide for data abstraction. The
same strategy was used by our group in previous reviews
[24,25].
Search Strategy
Search strategies were developed using systematic auto-
mated and manual searches. First, we conducted a com-
prehensive automated search of nine electronic
bibliographic databases -- including MEDLINE via
PubMed, EMBASE, Cochrane CENTRAL, AIDSLINE,
AMED, CINAHL, TOXNET, SciELO, and ISI-Web of Sci-
ence. Such databases were searched for the period
extending from January 1999 to June 2009; except for
AIDSLINE, which was searched from 1996 up to 2000,
when the inclusion of new citations was discontinued.
This search combined standardized search terms (key-
words and medical subject heading terms ? MESH) that
reflect key domains: (a) HIV/AIDS, (b) prevalence or
incidence, (c) location (Brazil), and (d) target populations
(i.e., FSW, MSM, IDU or non-injection drug users). Cita-
tions that intersect all four domains were downloaded
into the study database.
To reduce publication bias and gaps in the automated
search, we implemented four supplementary search strat-
egies to identify additional studies. First, we searched theMalta et al. BMC Public Health 2010, 10:317
http://www.biomedcentral.com/1471-2458/10/317
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published conference abstracts from HIV/AIDS and STD
conferences using the same domains as the automated
search. Second we searched the National Institutes of
Health's Computer Retrieval of Information on Scientific
Projects (CRISP) database http://projectreporter.nih.gov/
reporter.cfm   and the Brazilian online database on
researchers and their respective publications, research
projects and graduate students http://lattes.cnpq.br to
identify researchers working in the field of HIV/AIDS.
Third, we contacted authors of selected papers to obtain
additional data on upcoming publications. Finally, we
reviewed the reference lists of all selected studies for
additional citations. All studies identified through these
procedures that met our eligible criteria were entered
into the study database.
To be included in the review, studies should have mea-
sured HIV prevalence and/or incidence as the primary
outcome among at least one of the specific populations
under analysis.
Study Selection and Data Extraction
Using a predefined protocol, two investigators (MM, YL)
extracted data from peer-reviewed papers measuring/
estimating HIV prevalence or incidence among the
selected populations and independently assessed their
eligibility. Using standardized coding forms, each
selected paper was coded for study characteristics (study
date, location, study design [cross-sectional, cohort],
recruitment setting, participant characteristics (age, gen-
der, race/ethnicity, condom use, needle/syringe sharing),
and factors found to be associated with HIV-infection.
For those factors multivariable analyses were carried out.
Statistical Analysis
Standard meta-analytic methods were employed [26,27].
We chose a random-effects model for aggregating indi-
vidual effect sizes because it provides a more conserva-
tive estimate than a fixed-effects model of variance. This
approach generates more accurate inferences due to the
fact it recognizes the selected studies as a sample of all
potential studies and incorporates between-study vari-
ability in the overall pooled estimation [28,29]. HIV prev-
alence and the crude (non-adjusted) proportion of
participants recorded as HIV-positive by each study were
used to pool the overall proportion, using the DerSimo-
nian-Laird random-effects method [30,31].
The I2 index was calculated as a measure of the overall
variation in prevalence that was attributable to between-
study heterogeneity [32,33]. Higgins and Thompson [32]
proposed a tentative classification of I2 values with the
purpose of helping to interpret its magnitude. Thus, per-
centages of around 25% (I2 ≤ 25), 50% (I2 ≈ 50), and 75%
(I2 ≥ 75) were interpreted as low, medium, and high het-
erogeneity, respectively. According to a recent review
[34], the I2 index assesses not only heterogeneity in a
meta-analysis but also the extent of that heterogeneity. It
is considered a more appropriate procedure than the Q
test in assessing whether there is true heterogeneity
among the studies in a meta-analysis [33]. Experts have
demonstrated that the I2 index exhibits higher power with
a larger number of studies (>20) with an average sample
size higher than 80 individuals [34].
We anticipated a large between-study heterogeneity (I2
≥ 75), considering the characteristics of subpopulations
investigated and the study designs. According to standard
meta-analysis guidelines, when observational studies are
pooled, heterogeneity of populations (e.g. IDU and
NIDU), and of design (e.g. cross-sectional vs. cohort
studies) are expected [22,35].
Publication bias was examined through the use of a
funnel plot [36], and funnel plot asymmetry was further
tested by using Egger's method [37]. Sensitivity analyses
were performed to assess whether there were potential
heterogeneity sources and studies that may bias the anal-
yses. Studies potentially influencing heterogeneity were
therefore removed from the analyses and results com-
pared.
One forest plot was drawn for each population group
(FSW, MSM and drug users [including IDU and NIDU]).
Forest plots were sorted according to years data were col-
lected (starting with the older studies) to illustrate the
HIV-prevalence, its 95% confidence intervals (CI) and the
overall DerSimonian-Laird pooled estimate. For studies
addressing drug users we also conducted a mixed-effects
meta-regression model to assess the underlying reasons
for between-study heterogeneity. The small number of
eligible studies targeting FSW and MSM, and the absence
of key information that could influence between studies
heterogeneity precluded meta-regression analysis for
those populations [38].
For studies on drug users, results from univariate analy-
ses with p-values ≤ 0.20 were included in the multivari-
able analysis. The following covariates were included in
the meta-regression multivariable model: incarceration
(currently incarcerated vs. non-incarcerated partici-
pants), type of drug using population (IDU vs. NIDU),
region where the study was conducted (Brazilian south-
ern region vs. other regions), year of data collection (until
2001 or latter), and recruitment site (street vs. health cen-
ters' recruited participants). According to Hacker et al.
[39,40] IDU have played a central role in the HIV/AIDS
subepidemic in the southern border of Brazil, therefore
we dichotomized studies according to Brazilian region
(south vs. other regions). Recently, Bastos et al. [10,18]
described that AIDS incidence has been declining in Bra-
zil since 2002. Therefore, we dichotomized studies
according to data collection period as well.Malta et al. BMC Public Health 2010, 10:317
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Analyses were conducted using Stata version 10.0
(StataCorp, College Station, Tex) and graphics were gen-
erated using StatsDirect version 2.5.2 (StatsDirect Ltd,
Cheshire, England).
Results
Female sex workers
In the initial searches, 135 studies were selected (45 peer-
reviewed papers and 90 additional studies). Of these,
there was perfect agreement between reviewers on the
exclusion of 89 behavioral surveys without information
on HIV seroprevalence. In a second screening, 21 studies
conducted in other countries (rather assessing Brazilian
expatriates) were excluded. Agreement between review-
ers was also perfect on the second screening. A third
screening excluded 13 studies, primarily because authors
did not stratify results according to the actual engage-
ment of the interviewees in commercial sex. A final
screening excluded four other reviews. Agreement on the
two final screenings was also perfect. We thus included
eight eligible reports for full data extraction [41-48] (Fig-
ure 1).
Study characteristics and major study findings
Selected studies analyzed 3,625 FSW (range: 90-2712;
median: 143.5 participants), seven of them cross-sec-
tional studies and one of them a retrospective cohort
study. The largest study was conducted in 9 Brazilian cit-
ies and included 2,712 participants [47]. The majority of
participants were young women aged 30 years or less.
However, self-reported condom use across selected stud-
ies presented a great variability overall and for each spe-
cific study. Variability was higher with sexual clients than
with occasional and stable partners. According to the
largest study conducted with FSW in Brazil, condom use
was more than threefold greater when we compared sex-
ual intercourse among sexual clients and stable partners:
67.3% vs. 19.2% (Table 1). Only three studies conducted
multivariable analyses, which precluded additional
pooled analysis of factors putatively associated with the
outcome (HIV-prevalence).
According to Trevisol and Silva [45], covariates inde-
pendently associated with HIV prevalence included:
"having more than two sexual clients per day", "frequent
use of inhalants" and "inconsistent condom use". Pires
and Miranda [48] identified as key risk factors: "syphilis"
and "injection drug use".
The Brazilian Ministry of Health study [47] identified
"injection drug use" and "having an IDU partner" as cova-
riates independently associated with the outcome, as well
as syphilis and HCV infection. We kept the risk factors as
described in the original paper, despite the fact that, for
instance, HCV infection should be rather viewed as a bio-
marker of underlying risk behaviors (e.g. injecting drug
use), rather than an independent risk factor for HIV
infection (Table 1).
Meta-Analysis
After conducting a sensitivity analysis, we decided to
present the combined HIV prevalence separately, with
the inclusion or exclusion of one "outlier". The identifica-
tion of this study as an 'outlier' was not based on an a pri-
ori statistical criterion (e.g. two standard deviation of the
mean), but rather on a thorough evaluation and compari-
son of the study characteristics with all selected studies.
The inclusion of this study significantly decreased the
pooled prevalence, and increased the between-study het-
erogeneity (I2 = 81.9 vs. I2 = 56.8). The "outlier" study,
conducted by Benzaken and colleagues [46], was devel-
oped in a municipality with less than 100,000 inhabitants
located in the Tropical rain forest, in the state of Amazon,
and did not identify a single HIV-positive participant.
This absence of HIV-positive participants is likely due to
the study's sampling frame. Additional studies conducted
with FSW from the same region identified a prevalence of
2.6% [42].
The combined HIV prevalence across all studies was
5.1 (95% CI: 2.9-7.8), while the pooled HIV prevalence,
excluding this specific study, was 6.2 (95% CI: 4.4-8.3)
(see Figures 2a and 2b, respectively). The absence of
explicit data on key parameters and/or covariates that
might be associated with the between-studies heteroge-
neity (e.g. condom use) precluded meta-regression mod-
eling.
Figure 1 Flow Diagram of Studies Included in Analysis, CSW.
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Table 1: Characteristics of selected studies and AIDS prevalence among female sex workers from Brazil, 1998-2009.
Source N State Design (Period) Characteristics of Study Population Sexual behavior and HIV infection
Age [mean (range)] Ethnicity (%) Condom use (%) HIV prevalence Variables associated with 
prevalent HIV
Barroso et al. [41] 93 Rio de Janeiro Cross-sectional 
(2006)
NA NA NA 12.9% NA
Benzaken et al. [42] 114 Amazon Cross-sectional 
(2006)
29 (IQR1 : 22-38) NA NA 2.6% NA
Lacerda et al. [43] 175 São Paulo Cross-sectional 
(2005-06)
29 (18-62) Caucasian: 53.1%
Black: 8.0%
Mulatto: 34.9%
Others: 4.0%
Always use condom with client: 
73.1%
5.7% NA
Dutra & Vasques [44] 154 Amazon Cross-sectional 
(2005-06)
30.3 ± 8.8 Caucasian: 17,1%
Black: 13,3%
Mulatto: 69,6%
Always use condom: With 
stable partner: 36.3%
With occasional partner: 25.2%
2.6% NA
Trevisol & Silva [45] 90 Santa 
Catarina
Cross-sectional 
(2003-04)
27 ± 5.2 Caucasian: 85.6%
Black: 4.4%
Mulatto: 10.0%
Condom use:
Always: 16.7%
Sometimes: 77.8%
Never: 5.6%
6.7% ≤ 2 clients/day (p = 0.008) 
Infrequent condom use 
(p = 0.015) Use of inhalants (p 
= 0.053)
Benzaken et al.[46] 147 Amazon Cross-sectional 
(2000)
25.5 (12-54) NA NA 0.0% NA
Brazilian Ministry of 
Health [47]
2712 9 states Cross-sectional 
(2000-01)
Age group:
17-19: 8.1%
20-24: 25.0%
25-29: 20.7%
30-39: 26.8%
40-49: 14.0%
≥50: 5.3%
NA Always used condom on 
previous 6 months:
With sexual clients: 67.3%
With stable partner: 19.2%
Overall: 6.1%
Intervention 
group: 6.6%
Control group: 
5.6%
Injection drug use:
RR: 6.77 (3.44 - 13.17)
IDU partner:
RR: 2.70 (1.89 - 3.85)
Syphilis coinfection: RR: 3.56 
(2.00 - 6.29)
HCV coinfection:
RR: 11.26 (7.28 - 17.40)
Pires & Miranda [48] 140 Espírito Santo Retrospective 
Cohort (1993-
96)
25.9 ± 6.8 NA Always: 31.3%
Sometimes: 52.0%
Never: 16.7%
8.6% Injection drug use (p = 0,031)
Syphilis coinfection (p = 
0,014).
1 IQR - Interquartile rangeMalta et al. BMC Public Health 2010, 10:317
http://www.biomedcentral.com/1471-2458/10/317
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Men who have sex with men
In the initial searches, 168 studies were selected (115
peer-reviewed papers and 53 additional studies). Of
these, there was perfect agreement between reviewers on
the exclusion of 122 behavioral surveys which did not
measure HIV seroprevalence. In a second screening, 4
studies conducted in other countries were excluded.
Agreement between reviewers was also perfect on the
second screening. A third screening excluded 21 studies,
primarily because authors did not stratify results accord-
ing to homosexual practices. A final screening excluded
11 reviews. Agreement on the two final screenings was
also perfect. We thus included ten studies for full data
extraction [49-58](Figure 3).
Study Characteristics and major study findings
Selected studies analyzed 6,475 men who have sex with
men (range: 187-1,082; median: 639.5 participants), seven
of them cross-sectionals studies and three prospective
cohort studies. Szwarcwald et al. [51] conducted a large
cross-sectional study with Brazilian military conscripts,
while Ferreira et al. [50] analyzed a large sample of MSM
who were also IDU. The other studies were conducted in
large urban areas from Brazilian South and Southeast
regions [49,52-58].
The majority of participants were young MSM aged 30
years or less. Unprotected anal intercourse was com-
monly reported in the selected studies, but presented a
great variability according to the nature of the relation-
ship with their partner(s) - stable vs. occasional sex part-
ners - and sexual practice - receptive vs. insertive anal sex
(Table 2).
Carneiro et al. [54] identified almost a four-fold
increase in HIV prevalence among those men who
reported unprotected anal intercourse with occasional
partners (adjusted odds ratio - AOR: 3.7) and a greater
than three-fold risk of being infected among those of
black ethnicity (AOR: 3.4) The authors did not further
explore the association between black ethnicity and HIV
infection, compromising inferences about the proximal
risk factors putatively involved in such association (e.g.
attitudes toward safer behaviors, inconsistent use of con-
doms, etc.).
According to the study conducted by Harrison et al.
[58], factors found to be independently associated with
seroconversion in their sample of MSM were: "age < 25
years", "sex at the first encounter in the previous six
months", and a medical history for the following infec-
tions: HBV, gonorrhea or condyloma. (Table 2).
Meta-Analysis
Two studies were excluded from our pooled analysis
because their outcome was HIV-incidence instead of
prevalence [52,56]. After conducting a sensitivity analy-
Figure 2 a. Pooled Proportion of HIV Prevalence among CSW, all studies* b. Pooled Proportion of HIV Prevalence among CSW, 7 studies*.
b. a
Trevisol & Silva [45] 0.067 (0.025, 0.139)
BM of Health [47] 0.058 (0.049, 0.067)
Benzaken et al. [46] 0.000 (0.000, 0.025)
Pires & Miranda [48] 0.086 (0.045, 0.145)
Lacerda et al. [43] 0.057 (0.028, 0.103)
Trevisol & Silva [45] 0.067 (0.025, 0.139)
BM of Health [47] 0.058 (0.049, 0.067)
Pires & Miranda [48] 0.086 (0.045, 0.145)
*The combined data marker indicates the DerSimmonian-Laird combined proportion
0.00 0.05 0.10 0.15 0.20 0.25
Combined 0.050 (0.029, 0.077)
Benzaken et al. [42] 0.026 (0.005, 0.075)
Barroso et al. [41] 0.129 (0.068, 0.215)
Dutra & Vasques [44] 0.026 (0.007, 0.065)
Lacerda et al. [43] 0.057 (0.028, 0.103)
HIV Prevalence (95% Confidence Interval)
0.00 0.05 0.10 0.15 0.20 0.25
Combined 0.061 (0.043, 0.082)
Benzaken et al. [42] 0.026 (0.005, 0.075)
Barroso et al. [41] 0.129 (0.068, 0.215)
Dutra & Vasques [44] 0.026 (0.007, 0.065)
Lacerda et al. [43] 0.057 (0.028, 0.103)
HIV Prevalence (95% Confidence Interval)
*The combined data marker indicates the DerSimmonian-Laird combined proportion
Figure 3 Flow Diagram of Studies Included in Analysis, MSM.
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Table 2: Characteristics of selected studies and AIDS prevalence among men who have sex with men from Brazil, 1998-2009.
Characteristics of Study Population Sexual behavior and HIV infection
Source N State Design (Period) Age Ethnicity (%) Condom use (%) HIV prevalence Variables associated 
with prevalent HIV
Tun et al. [49] 658 Campinas Cross-sectional (2006) Median: 23 NA Unprotected sex Overall sample: 7% 
(5-11%)
NA
MSM engaged in sex work:
Insertive anal sex: 21.0% MSM engaged in 
sex work: 14%
Receptive anal sex: 22.0%
Vaginal sex: 23.0%
MSM not engaged in sex work: MSM not engaged 
in sex work: 6%
Insertive anal sex: 5.0%
Receptive anal sex: 5.0% Participants 
between 14-19 
years: 4%
Vaginal sex: 6.0%
Unprotected receptive anal sex 
with at least one partner: 30% (CI: 
26-35%)
Unprotected receptive anal sex 
with ≥ 2 partners: 7% (4-10%)
Unprotected anal/vaginal sex 
with female, previous 2 months: 
75% (37-91%)
Ferreira et al. 
[50]
1872 Brazil Cross-sectional (2000-
01)
28 ± 8.2 Non white: 51.1% Always use condom: 36.4% 51.9% NA
Szwarcwald 
et al.[51]
8983 Brazil Cross-sectional (2002) 17-20 years: 94.0% NA Always use condom: 34.1% 0.564 (0.278-0.850) NA
Schechter et 
al. [52]
200 Rio de 
Janeiro
Prospective cohort 
(1998-2001)
28 White: 47.0% Unprotected anal sex, previous 6 
months:
NA5 NA
Black: 21.0% PEP5 : 47.1%
Mulatto: 7.0% Non-PEP: 36.4%
Others: 26.0%
Barcellos et 
al. [53]
4616 Porto 
Alegre
Cross-sectional (1996) NA NA NA 24.1% NAM
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Carneiro et 
al. [54]
621 Belo 
Horizonte
Cross-sectional (1994-
1999)
Mean: 28 NA NA 9.8% Unprotected sex w/
occasional partner: AOR7 : 
= 3.7 (: 1.1 -11.9)
Receptive anal sex w/
occasional partner: AOR = 
2.8 (0.9- 8.9)
Black vs. Non-black:
AOR = 3.4 (1.3-10.6)
Sutmöller et 
al.[55]
1165 Rio de 
Janeiro
Prospective cohort8 
(1994-1998)
Range: 18-50 NA NA 24.1% NA
Carneiro et 
al. [56]
470 Belo 
Horizonte
Cross-sectional (1994-
1999)
26.9 ± 6.8 Mulatto: 51.8%
White: 40.9%
Black: 7.3%
Unprotected anal sex with 
occasional partner: 41.3%9
NA NA
Brazilian 
Ministry of 
Health [57]
642 São Paulo Cross-sectional (1994-
1999)
28 NA Stable partner 8.8% NA
Receptive anal sex: 33.9%
Insertive anal sex: 36.0%
Occasional partner
Receptive anal sex: 13.7%
Insertive anal sex: 15.3%
Harrison et al. 
[58]
849 Rio de 
Janeiro
Prospective cohort10 
(1995-97)
HIV+: 28.8 HIV+: 63.6% Unprotected receptive anal sex: 11.7% Penile or anal lesion (p < 
0.01)
HIV-: 28.2 HIV-: 50.7 HIV+: 59.6% Hepatitis B seropositivity 
(p < 0.01)
HIV-: 43.6%
Unprotected insertive anal sex: History of syphilis (p < 
0.01)
HIV+: 34.3%
HIV-: 30.8%
2 All MSM and injection drug users (IDU)
3 MSM sample size among 30,970 military conscripts
4 PEP: Post-sexual Exposure Prophylaxis
5 Only incidence rates are available
6 Homo and bisexuals included
7 AOR: Adjusted Odds Ratio
8 Baseline data
9 Among 265 participants reporting anal sex
10 Baseline data
Table 2: Characteristics of selected studies and AIDS prevalence among men who have sex with men from Brazil, 1998-2009. (Continued)Malta et al. BMC Public Health 2010, 10:317
http://www.biomedcentral.com/1471-2458/10/317
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sis, we decided to exclude two outlier studies from the
pooled HIV-prevalence, since both analyzed very specific
subgroups of MSM that are very different from the popu-
lation accessed by all other selected studies. The study by
Szwarcwald et al. [51] was conducted with Brazilian mili-
tary conscripts, a population with distinct characteristics
from those studied in the other papers, and found a very
low HIV-prevalence (0.564, 95% CI: 0.278-0.850). The
primary aim of this large survey was not to assess the
behavioral characteristics of young gay men (aged 17-18
years old), but rather to assess the profile of young con-
scripts as a whole. The small number of self-declared gay
or bisexual conscripts precluded further analysis for this
specific subpopulation.
On the other hand, the study by Ferreira et al. [50] was
conducted among male injection drug users who also
reported homosexual behaviors, and found a very high
HIV prevalence (51.9%). Even after excluding those stud-
ies, a large between-study heterogeneity remained (I2 =
97.1%), and funnel plot asymmetry was evident. In the
sensitivity analysis we were not able to attribute the iden-
tified asymmetry to any single study. Studies were con-
ducted using different designs (cohort vs. cross-sectional
surveys), over many years (from 1994 to 2006) and in very
different settings (research centers, public health facili-
ties, and NGOs), therefore compromising the reliability
of our pooled analysis. Due to the small number of stud-
ies and its great variability , we were unable to conduct
subgroup analyses. Those caveats should be also consid-
ered in the analysis of pooled HIV prevalence from the
remaining 6 studies: 13.6 (95% CI: 8.2-20.2, Figure 4). The
absence of key covariates and/or parameters that could
explain the between-studies heterogeneity precluded
meta-regression modeling.
Injection and non-injection drug users
In the initial searches, 337 studies were selected (183
peer-reviewed papers and 154 additional studies). Of
these, there was perfect agreement between reviewers on
the exclusion of 117 behavioral surveys without informa-
tion on HIV seroprevalence. In a second screening, 29
studies conducted in other countries were excluded.
Agreement between reviewers was also perfect on the
second screening. A third screening excluded 69 studies,
primarily because authors did not stratify results accord-
ing to the actual use of substances. The remaining 67
reviews were also excluded, as well as 26 studies which
provided information already extracted from more
recently published studies on the same population, by the
same research group (i.e. excluded studies published by
the same research group describing partial findings).
Agreement on the three final screenings was perfect. We
thus included twenty nine reports for full data extraction
[39,53,59-85] (Figure 5).
Study Characteristics and major study findings
Selected studies analyzed 13,063 injection and non-injec-
tion drug users (range: 89-1544; median: 250 partici-
pants). The vast majority of them were cross-sectionals
studies (n = 25), but there were two prospective cohorts
and two case-control studies. Two manuscripts reported
findings from a single multicenter study conducted in
Brazil with IDU population - AjUDE Brasil I and II
[65,67]. The vast majority of selected studies were con-
ducted with street drug users from large urban cities
located in Brazilian South, Southeast, and the southern-
most part of the Northeast region [39,53,59-64,66,68-85].
Four studies were conducted with incarcerated popula-
Figure 4 Pooled Proportion of HIV Prevalence among MSM.*
Tun et al. [49] 0.07 (0.06, 0.10)
Barcellos et al. [53] 0.24 (0.20, 0.28)
Harrison et al. [58] 0.12 (0.10, 0.14)
BM of Health [57] 0.11 (0.09, 0.13)
Sutmöller et al.[55] 0.27 (0.24, 0.30)
Carneiro et al. [54] 0.10 (0.08, 0.12)
0.0 0.1 0.2 0.3
Combined 0.14 (0.09, 0.21)
HIV Prevalence (95% Confidence Interval)
*The combined data marker indicates the DerSimmonian-Laird combined proportion
Figure 5 Flow Diagram of Studies Included in Analysis, IDU and 
DU.
337 Full-Text Articles Reviewed by
52 Conference Abstracts
45 MPH or PhD Thesis
57 Books, reports or unpublished papers
183 Abstracts of Full-Text Articles
Identified in Electronic Databases
Individual Researchers for Eligibility
29 Studies Eligible by Consensus Included on Analysis
69 conducted with other populations or didn’t stratify 
participants according to history of drug use (drug 
users vs. never drug users)
29 conducted in other countries
67 systematic review
117 studies without the outcome of interest (HIV-
prevalence)
26 studies with repeated informationMalta et al. BMC Public Health 2010, 10:317
http://www.biomedcentral.com/1471-2458/10/317
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tions, and their findings were stratified according to pre-
vious drug use [60,72,78,83].
Most participants were young NIDU/IDU aged 30
years or less. Needle sharing was commonly reported by
the studies under analysis, but under a great variability.
According to the study conducted by Albuquerque [80],
15.4% of IDU shared syringe/needles in the previous six
months. Guimarães et al. [77] identified that 92.3% of
HTLV-infected IDU have shared needle/syringes. Injec-
tion drug use has been declining in recent years as shown
by different papers presenting the findings of studies car-
ried out in different Brazilian settings. Recently published
studies tend to recruit larger samples of crack cocaine
and/or snorted cocaine users rather than injection drug
users (Additional file 1).
The majority of selected studies conducted multivariate
analyses, and consistently identified injection drug use
and syringe/needle sharing as key predictors of HIV-
infection [53,59,60,64-66,69,71,72,74-76,81,83,85]. Key
predictors of HIV-infection in the context of sexual risk
behaviors included reporting to have had an HIV-positive
or IDU sexual partner, engagement in sex work and male-
to-male sex [39,53,59,64,65,67,69,72,81,83]. According to
a few studies, a history of previous incarceration was
found to be associated with HIV-infection [39,53,60,67].
Reports on infection by HCV and/or different sexually
transmitted infections (STIs) have been identified by
some authors as predictors of HIV-infection, but should
rather be viewed as biomarkers of sexual and injection
risk behaviors associated with both HIV and the acquisi-
tion of other STIs and blood-borne infections - additional
file [53,67,81,83].
Meta-Analysis
Eight studies were excluded from our meta-analysis due
to different reasons. The study conducted by De Boni and
Pechansky [75] did not provide the HIV-prevalence for
the overall sample and the study conducted by Guimarães
et al. [78] with male inmates did not stratify their results
according to different patterns of drug use. Two studies
were conducted with participants who were co-infected
with HIV and HCV, a specific subgroup that could bias
the analysis toward people under higher risk and/or
severely ill [65,66]. The study conducted by Caiaffa and
c o l l e a g u e s  [ 7 3 ]  a n a l yz ed  p a rt  o f  t h e  d a t a s e t  o f  A j U D E
Brasil I and II projects, later published as comprehensive
papers presenting the findings relative to the final dataset
[67]. Four studies presented preliminary results on spe-
cific behaviors or genetic/virologic characteristics of drug
users enrolled by the WHO Drug Injection Study Phase
II, conducted in Rio de Janeiro [39,70,77,80]. Once again,
we decided to include the most recent and complete anal-
y s i s  o f  t h i s  d a t a s e t  [ 3 9 ] .  I n  s u m ,  w h i l e  o u r  s y s t e m a t i c
review analyzed 29 studies, we included only 22 studies in
the meta-analysis.
Even after excluding studies defined as outliers, a large
between-study heterogeneity remained (I2 = 98.6%), with
biased indicators and funnel plot asymmetry. In the sen-
sitivity analysis, we were not able to ascribe the identified
asymmetry to any specific study. Subgroup meta-analysis
including only studies evaluating IDU remained highly
heterogeneous (I2= 98.2%), as well as the pooled analysis
of studies accessing only non-injection drug users (I2 =
97.1%). When we stratified our studies according to
incarcerated vs. non-incarcerated drug users, the hetero-
geneity remained (I2 = 95.1% vs. 98.7%).
The study conducted by Caiaffa et al [67] reports HIV-
seroprevalence for two different multicenter studies
(AjUDE Brasil I, conducted in 1998, and AjUDE Brasil II,
conducted in 2000-01), therefore we divided such studies
in our pooled analysis. The same strategy was used to
pool the study from De Boni et al. [68] (one substudy was
conducted in Rio de Janeiro and another in Porto Alegre),
as well as the study published by Mesquita et al. [79] (pre-
senting three different cross-sectional studies, conducted
in 1991/92, 1994/96 and 1999). Studies were conducted in
very different settings (drug addiction treatment centers,
HIV-testing facilities and NGOs), accessed highly hetero-
geneous groups (e.g. female crack users vs. drug users
under addiction treatment and street-recruited injection
drug users) and were conducted over a long period of
time (from 1991 to 2004), therefore compromising the
reliability of our pooled analysis. Those caveats should be
considered when analyzing the combined HIV preva-
lence across studies: 23.1 (95% CI: 16.7-30.2, Figure 6).
There has been discussion in the literature about
whether people have changed their risk behaviors in the
HAART era [1]. In an attempt to further contribute to
this discussion, we aggregated studies according to period
of data collection (pre-HAART era [until 1995] vs. pos-
HAART era [since 1996]). Thirteen studies were con-
ducted with IDU/NIDU in the pre-HAART era
[63,64,68,69,71,77,79,81,83,85] and thirteen in the pos-
HAART era [53,74,76,82,67,39,79,59,67,62,61,60,72].
Studies conducted in the pre-HAART period identified a
higher HIV-prevalence: 29.5% (95% CI: 20.0 - 39.9) than
studies conducted in the post-HAART period: 17.8%
(95% CI: 9.09 - 28.8), see Figures 7aand 7b, respectively.
A meta-regression model (Table 3) was fitted to evalu-
ate major predictors of the between-studies heterogene-
ity, including the following covariates: "incarceration",
drug using patterns (IDU vs. NIDU), "Brazilian region"
(South vs. Southeast and Northeast), "study period"
(1991-2001 vs. 2002-2004), and "recruitment site" (street
recruited drug users vs. drug addiction or HIV testing
facilities). After adjustment, only drug using patterns
remained associated with the between-study heterogene-
ity (P-value < 0.0001). For studies accessing injection
drug users, the AOR was 7.13 (95% CI: 2.52-20.20), whenMalta et al. BMC Public Health 2010, 10:317
http://www.biomedcentral.com/1471-2458/10/317
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compared to studies evaluating non-injection drug users
(Table 3).
Discussion
This is to our knowledge the first meta-analysis of HIV
prevalence from three highly vulnerable populations car-
ried out in Brazil: FSW, MSM and IDU/NIDU. Overall,
the odds of having HIV infection are markedly and con-
sistently higher among those populations than in the gen-
eral population of adults of reproductive age. This latter
has been stabilized around 0.6% since 2000 in Brazil
[16,18,86].
There are a number of limitations to our study. FSW,
MSM and drug users are often difficult to access and to
enroll in surveys because of the social stigma associated
with their behaviors and criminalization of drug use.
These barriers may limited both the number and quality
of studies identified, particularly those assessing FSW (n
= 8) and MSM (n = 10). Drug users have been more sys-
tematically surveyed in Brazil, particularly due to surveys
carried out in collaboration with international institu-
t i o n s,  s u c h  a s  t h e  W o r l d  H e a l t h  O r g a n i z a t i o n  (W H O )
and the National Institute on Drug Abuse (NIDA/NIH).
The majority of studies cited in this analysis used small
convenience samples and were cross-sectional.
Gaps identified amongst the data and the resulting lack
of accuracy of the pooled HIV/AIDS prevalence for MSM
and FSW seem to be associated with the fragmentary
character of sero- and behavioral surveillance targeting
those populations in Brazil. This scenario is likely to be
modified in the near future, with the implementation by
the Brazilian Ministry of Health of biannual seroepidemi-
ological studies targeting MSM, FSW and IDU/NIDU.
The first round of such studies was conducted in 2009,
Figure 6 Pooled Proportion of HIV Prevalence among DU/IDU.*
Pechansky et al [74] 0 285 (0 222 0 354)
Barcellos et al. [53] 0.202 (0.176, 0.231)
Pechansky et al. [64] 0.206 (0.186, 0.228)
Pechansky et al. [71] 0.226 (0.187, 0.269)
De Boni et al. - PoA [68] 0.650 (0.483, 0.794)
De Azevedo et al. [63] 0.207 (0.158, 0.264)
Pechansky et al. [69] 0.259 (0.205, 0.320)
Guimaraes et al. [77] 0.226 (0.189, 0.267)
Zanetta et al. [83] 0.038 (0.026, 0.055)
Telles et al. [85] 0.287 (0.204, 0.382)
Surrat [81] 0.087 (0.073, 0.102)
Mesquita et al. - wave 2 [79] 0.652 (0.565, 0.732)
Dourado et al. [84] 0.495 (0.427, 0.564)
De Boni et al. - RJ [68] 0.159 (0.103, 0.228)
Mesquita et al. - wave 1 [79] 0.631 (0.562, 0.696)
0.0 0.2 0.4 0.6 0.8
Combined 0.234 (0.169, 0.306)
Coelho [72] 0.345 (0.179, 0.543)
Coelho et al. [60] 0.057 (0.035, 0.088)
Bassols et al. [61] 0.114 (0.062, 0.187)
Nunes et al. [62] 0.016 (0.002, 0.057)
Caiaffa et al. - AjUDE II [67] 0.459 (0.425, 0.493)
Strazza et al. [59] 0.166 (0.116, 0.227)
Mesquita et al - wave 3 [79] 0.417 (0.323, 0.515)
Hacker et al. [39] 0.080 (0.060, 0.105)
Caiaffa et al. - AjUDE I [67] 0.523 (0.463, 0.582)
Bastos et al. [82] 0.009 (0.001, 0.032)
Turchi et al. [76] 0.049 (0.035, 0.066)
Pechansky et al. [74] 0.285 (0.222, 0.354)
HIV Prevalence (95% Confidence Interval)
*The combined data marker indicates the DerSimmonian-Laird combined proportion
Figure 7 a. Pooled Proportion of HIV Prevalence among DU/IDU - Pre-HAART* b. Pooled Proportion of HIV Prevalence among DU/IDU - Pos-
HAART*.
a
Zanetta et al [83] 00 4( 00 3 00 5 )
Telles et al. [85] 0.29 (0.20, 0.38)
Surrat [81] 0.09 (0.07, 0.10)
Mesquita et al. - wave 2 [79] 0.65 (0.57, 0.73)
Dourado et al. [84] 0.50 (0.43, 0.56)
De Boni et al. - RJ [68] 0.16 (0.10, 0.23)
Mesquita et al. - wave 1 [79] 0.63 (0.56, 0.70)
b.
Hacker et al. [39] 0.080 (0.060, 0.105)
Caiaffa et al. - AjUDE I [67] 0.523 (0.463, 0.582)
Bastos et al. [82] 0.009 (0.001, 0.032)
Turchi et al. [76] 0.049 (0.035, 0.066)
Pechansky et al. [74] 0.285 (0.222, 0.354)
Barcellos et al. [53] 0.202 (0.176, 0.231)
*The combined data marker indicates the DerSimmonian-Laird combined proportion
0.0 0.2 0.4 0.6 0.8
Combined 0.29 (0.20, 0.40)
Pechansky et al. [64] 0.21 (0.19, 0.23)
Pechansky et al. [71] 0.23 (0.19, 0.27)
De Boni et al. - PoA [68] 0.65 (0.48, 0.79)
De Azevedo et al. [63] 0.21 (0.16, 0.26)
Pechansky et al. [69] 0.26 (0.21, 0.32)
Guimaraes et al. [77] 0.23 (0.19, 0.27)
Zanetta et al. [83] 0.04 (0.03, 0.05)
HIV Prevalence (95% Confidence Interval)
*The combined data marker indicates the DerSimmonian-Laird combined proportion
0.0 0.2 0.4 0.6 0.8
Combined 0.179 (0.091, 0.288)
Coelho [72] 0.345 (0.179, 0.543)
Coelho et al. [60] 0.057 (0.035, 0.088)
Bassols et al. [61] 0.114 (0.062, 0.187)
Nunes et al. [62] 0.016 (0.002, 0.057)
Caiaffa et al. - AjUDE II [67] 0.459 (0.425, 0.493)
Strazza et al. [59] 0.166 (0.116, 0.227)
Mesquita et al - wave 3 [79] 0.417 (0.323, 0.515)
HIV Prevalence (95% Confidence Interval)Malta et al. BMC Public Health 2010, 10:317
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but no peer-reviewed paper was published so far on such
studies.
MSM, FSW and drug users tend to congregate in urban
areas, at least partially explaining why the vast majority of
reported studies are urban; again, this may limit the gen-
eralizability of our study findings, further complicated by
the fact that most studies were carried out in large metro-
politan areas of the most industrialized regions in Brazil.
Publication bias tends to affect the results of meta-analy-
ses, both in terms of clinical and public health research,
and may compromise the accuracy of pooled measures
[87].
To minimize the effect of publication bias, gray litera-
ture (e.g. national and international conferences and local
reports) were included and researchers were directly con-
tacted to obtain upcoming publications. We conducted a
sensitivity analysis to assess each study impact on the
pooled HIV-prevalence for each population group. Such
an approach is important in assessing the validity of the
assumptions made for the statistical calculations in meta-
analyses [37,88]. Studies that may have an influence on
the pooled analyses were removed. Results were then
compared and a few studies were included only in the
systematic review in order to control for potential biases.
Unfortunately information on methodological quality of
selected studies was insufficient to allow a detailed analy-
sis of their quality.
Despite these limitations, this meta-analysis draws its
strength from the pooled estimates for a large aggregate
sample size of drug users (N = 13,063), while the aggre-
gate sample size for FSW and MSM were not very large
(N = 3,625 and 6,475, respectively). The small number of
studies assessing FSW (N = 8) and MSM (N = 10), basi-
cally analyzing data from small-scale samples precluded
further analysis and lead us to conclude that our meta-
analysis for those two populations would not be conclu-
sive [89].
Due to the significant heterogeneity identified in our
pooled HIV prevalence for FSW (I2 = 81.9), MSM (I2 =
97.1%), and drug users (I2 = 98.6%), our pooled HIV-prev-
alence is likely not to be valid as an accurate measure of
risk. Subgroup analysis were not conducted for studies
addressing FSW and MSM, due to the small number of
studies addressing those populations and the lack of key
variables that could guide such analyses. The subgroup
analysis of studies on drug users highlighted high
between-study heterogeneity. These trends of high HIV
prevalence among FSW, MSM and IDU/NIDU speak in
favor of the urgent need to improve targeted prevention
strategies to those at-risk populations, particularly in the
context of a developing country providing a comprehen-
sive array of prevention interventions and HIV-treatment
free of charge to any eligible individual living with AIDS.
The critical factor in making adequate HIV estimates in
countries with low-level or concentrated epidemics is the
Table 3: Covariates associated with "between-studies" heterogeneity according to multivariable logistic regression, Injection and non-
injection drug users.
Variable OR (95%CI) AOR (95%CI)
Incarceration
Currently incarcerated 2.37 (0.58 - 9.70) --------
Non-incarcerated 1.00
Drug use
Injection drug use 5.57 (2.50 - 12.39)** 7.13 (2.52 - 20.20)**
Non-injection drug use 1.00 1.00
Brazilian Region
South 1.86 (0.57 - 6.08) --------
Southeast and Northeast 1.00
Study Period
1991-2001 1.72 (0.32 - 9.30) --------
2002-2004 1.00
Recruitment site
Street recruited drug users 2.28 (0.83 - 6.25)* 0.68 (0.24 - 1.91)
Drug addiction or VCT facilities 1.00 1.00
Abbreviations: CI - Confidence Interval; OR - Odds Ratio;
AOR - Adjusted Odds Ratio (adjusted for all variables listed in the table)
* p-value = 0.10; **p-value < 0.0001Malta et al. BMC Public Health 2010, 10:317
http://www.biomedcentral.com/1471-2458/10/317
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availability of data. Countries that have serological and
behavioral data for most at-risk groups may profit from
better and more comprehensive estimates to inform poli-
cymaking and monitoring [90]. Exception made to the
US, a few countries from Western Europe, and African
countries where many different cooperative studies have
been carried out assessing different populations and geo-
graphic areas such as Uganda, similar limitations as the
ones identified by our group have been observed in most
countries and have been associated with gross under and
overestimates, such as the ones respecting India, later
corrected by more recent studies [91].
Comprehensive information about vulnerable popula-
tions, behaviors that place people at risk, and knowledge
of the current status and trends of infection rates among
those populations are an essential component of sound
programmatic decisions. In this sense, our pooled analy-
ses may help to inform public policies but also to high-
light the limitations of available data in Brazil.
The small number of studies on FSW and MSM, and
the lack of key information that could help to better
understand between-studies heterogeneity precluded
meta-regression analyses for those subpopulations [38].
For studies addressing the drug using population, meta-
r e g r e s s i o n  a n a l y s i s  i d e n t i f i e d  t h a t  i n j e c t i o n  d r u g  u s e r s
had a seven-fold increase in their risk to be HIV-infected,
when compared to non-injection drug users. The mea-
sures of association among drug users seem to be consis-
tent across injection and non-injection drug users,
incarcerated and non-incarcerated participants, irrespec-
tively of the geographic regions where they have been
surveyed, the study period and the recruitment site.
Those findings speak in favor of the external validity of
many individual studies on drug using populations car-
ried out in Brazil.
Conclusions
The study results constitute a clear call to action on three
fronts: surveillance, research, and prevention. The vari-
ous analyses completed for this study may not necessarily
explain complex differences in HIV epidemic dynamics,
but bring additional evidence of high HIV prevalence
rates among FSW, MSM, and drug users. HIV surveil-
lance efforts should take into account the high burden of
HIV among those vulnerable populations and expand
surveillance strategies to access hidden populations.
Social science, epidemiologic, and behavioral research
should use standardized data collection tools to assess
prevalence of HIV risk behaviors, knowledge about HIV,
and social and sexual network interactions, therefore
increasing our ability to cross-compare different studies.
Ethnographic assessments could further explore the cul-
tural and behavioral nuances of FSW, MSM, and drug
users and help to refine data collection instruments.
Advocacy and a non-discriminatory attitude may favor a
better access to such hard-to-reach populations, fostering
renewed HIV prevention, voluntary counseling and test-
ing, and prompt referral to treatment.
Notably, there exists a risk that demonstrating high
HIV prevalence rates among FSW, MSM and drug using
populations will further contribute to the stigmatization
already experienced by those populations. However, in
Brazil (as in most countries), funds for prevention are
generally allocated based on perceived needs; thus, the
risk of increasing stigma must be balanced by the poten-
tial benefits of successfully advocating for dedicated
funding resources for those populations and the agile
referral to treatment in the context of universal access to
HAART. Surveillance, research, and prevention efforts
should work together to improve and disseminate cur-
rently available strategies targeting those populations in
Brazil.
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